This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Pioglitazone in prediabetes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pioglitazone is known to improve insulin sensitivity, glycaemic control, hypertension and dyslipidaemia in people with T2DM (1).

Pioglitazone:

  • decreases fasting and postprandial plasma glucose levels by improving the sensitivity of hepatic and peripheral (muscle) tissue to insulin

A systematic review concluded that "Pioglitazone reduced or delayed the development of T2DM in people at increased risk of T2DM compared with placebo (low-certainty evidence) and compared with no intervention (moderate-certainty evidence). .. unclear whether the effect of pioglitazone is sustained once discontinued. Pioglitazone compared with metformin neither showed advantage nor disadvantage regarding the development of T2DM in people at increased risk (low-certainty evidence)."

Reference:

  • Schernthaner G et al. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 2013;36 Suppl 2:S155-61. [PMID: 23882041]
  • Ipsen EO et al. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No.: CD013516. DOI: 10.1002/14651858.CD013516.pub2.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.